Abstract #0067
Differentiation Between Progressive Disease and Treatment Necrosis in Patients with Glioblastoma using Dynamic Contrast Enhancement MRI
Moran Artzi 1,2 , Gilad Liberman 1,3 , Guy Nadav 1,4 , Deborah T Blumenthal 5 , Felix Bokstein 5 , Orna Aizenstein 1 , and Dafna Ben Bashat 1,6
1
Functional Brain Center, Tel Aviv Sourasky
Medical Center, Tel Aviv, Israel,
2
Sackler
Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel,
3
Department of Chemical Physics,
Weizmann Institute, Rehovot, Israel,
4
Faculty
of Engineering, Tel Aviv University, Tel Aviv, Israel,
5
Neuro-Oncology
Service, Tel Aviv Sourasky Medical Center, Tel Aviv,
Israel,
6
Sackler
Faculty of Medicine and Sagol School of Neuroscience,
Tel Aviv University, Tel Aviv, Israel
Differentiation between progressive-disease (PD) and
treatment-necrosis (TN) in patients with Glioblastoma
remains a major clinical challenge. In this study the
enhanced tumor area was automatically identified from
the raw DCE data using ICA. Voxel-based classification
was performed using SVM based on the DCE pharmacokinetic
parameters in eighteen patients scanned longitudinally
(total of 60 MRI scans). Significant differences were
obtained between transfer-constants, plasma-volume and
bolus-arrival-time in the different tissue classes (PD
and TN), and compared to NAWM. High sensitivity (89.3%)
and specificity (89.4%) were obtained using two-fold
cross-validation design. Classification results were
validated by a senior neuro-radiologist and supported by
MRS.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
